AU2023390489A1 — Methods for treating immune thrombocytopenia in subjects with cognitive impairment by administering rilzabrutinib
Assigned to Principia Biopharma Inc · Expires 2025-07-24 · 1y expired
What this patent protects
Methods for treating immune thrombocytopenia in a subject with cognitive impairment comprising administering at least one compound chosen from (R)-2-[3-[4-amino- 3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4- methyl-4-[4-(oxetan-3-yl)piperazi…
USPTO Abstract
Methods for treating immune thrombocytopenia in a subject with cognitive impairment comprising administering at least one compound chosen from (R)-2-[3-[4-amino- 3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4- methyl-4-[4-(oxetan-3-yl)piperazin-1yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.
Drugs covered by this patent
- Wayrilz (RILZABRUTINIB) · Genzyme Corp
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.